Recent studies have shown that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can significantly lower Lp(a) levels 45, 46, potentially offering benefits in thrombus prevention for AF patients. The gene discussed is PCSK9; the disease is atrial fibrillation.